Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 8, 2011, Pages 1870-1876

  Luszczki, Jarogniew J ^a,b   Andres Mach, Marta ^b   Barcicka Klosowska, Beata ^a   Florek Luszczki, Magdalena ^b   Haratym Maj, Agnieszka ^b   Czuczwar, Stanislaw J ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Cannabinoids; Pentylenetetrazole; Pharmacokinetic pharmacodynamic interactions; WIN 55,212 2 mesylate

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CLONAZEPAM; ETHOSUXIMIDE; PENTETRAZOLE; PHENOBARBITAL; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLONIC SEIZURE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; TASK PERFORMANCE;

ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; BENZOXAZINES; BRAIN; CANNABINOID RECEPTOR AGONISTS; CLONAZEPAM; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ETHOSUXIMIDE; HAND STRENGTH; MALE; MICE; MORPHOLINES; NAPHTHALENES; PENTYLENETETRAZOLE; PHENOBARBITAL; SEIZURES; VALPROIC ACID;

EID: 82455210955     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.07.001     Document Type: Article

References (53)

1. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996, 91:1585-1614.
2. Bahremand A., Nasrabady S.E., Shafaroodi H., Ghasemi M., Dehpour A.R. Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB 1 agonist ACEA in the pentylenetetrazole-induced seizure in mice. Epilepsy Res 2009, 84:110-119.
3. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle methode simple pour explorer l'action tranquilisante: le test de la cheminee. Med Exp (Basel) 1960, 3:81-84.
4. Brodie M.J., Schachter S.C. Fast facts. Epilepsy 2001, Health Press, Oxford. second ed.
5. Browne T.R., Holmes G.L. Epilepsy. N Engl J Med 2001, 344:1145-1151.
6. Childers S.R., Deadwyler S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 1996, 52:819-827.
7. Chiu P., Olsen D.M., Borys H.K., Karler R., Turkanis S.A. The influence of cannabinoid and delta-9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 1979, 20:365-375.
8. Consroe P., Wolkin A. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977, 201:26-32.
9. Deadwyler S.A., Hampson R.E., Mu J., Whyte A., Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 1995, 273:734-743.
10. Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000, 41:1364-1374.
11. Dudra-Jastrzebska M., Andres-Mach M.M., Ratnaraj N., Patsalos P.N., Czuczwar S.J., Luszczki J.J. Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. Seizure 2009, 18:607-614.
12. Falenski K.W., Carter D.S., Harrison A.J., Martin B.R., Blair R.E., DeLorenzo R.J. Temporal characterization of changes in hippocampal cannabinoid CB1 receptor expression following pilocarpine-induced status epilepticus. Brain Res 2009, 1262:64-72.
13. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995, 48:443-450.
14. Gholizadeh S., Shafaroodi H., Ghasemi M., Bahremand A., Sharifzadeh M., Dehpour A.R. Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 2007, 53:763-770.
15. Hayase T., Yamamoto Y., Yamamoto K. Protective effects of cannabinoid receptor agonist against cocaine and other convulsant-induced toxic behavioural symptoms. J Pharm Pharmacol 2001, 53:1525-1532.
16. Henry D.J., Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett 1995, 186:91-94.
17. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
18. Howlett A.C. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995, 35:607-634.
19. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Porrino L.J. Cannabinoid physiology and pharmacology: 30years of progress. Neuropharmacology 2004, 47(Suppl. 1):345-358.
20. Huang C.C., Lo S.W., Hsu K.S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 2001, 532:731-748.
21. Johannessen-Landmark C., Patsalos P.N. Interactions between antiepileptic drugs and herbal medicines. Bol Latinoam Caribe Plant Med Aromaticas 2008, 7:108-118.
22. Karler R., Cely W., Turkanis S.A. The anticonvulsant activity of cannabidiol and cannabiol. Life Sci 1973, 13:1527-1531.
23. Karler R., Cely W., Turkanis S.A. Anticonvulsant properties of delta-9-tetrahydrocannabinol and other cannabinoids. Life Sci 1974, 15:931-947.
24. Koda S., Takeda S., Onimaru H., Akada S., Sakamoto A. Cannabinoid suppressed bicuculline-induced convulsion without respiratory depression in the brainstem-spinal cord preparation from newborn rats. Biomed Res 2005, 26:241-247.
25. Kuster J.E., Stevenson J.I., Ward S.J., D'Ambra T.E., Haycock D.A. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 1993, 264:1352-1363.
26. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
27. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 2000, 9:464-468.
28. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949, 96:99-113.
29. Löscher W. Current status and current directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2002, 23:113-118.
30. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
31. Luszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J. Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2009, 602:298-305.
32. Luszczki J.J., Czarnecki R., Wojtal K., Borowicz K.K., Czuczwar S.J. Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm 2008, 115:1485-1493.
33. Luszczki J.J., Misiuta-Krzesinska M., Florek M., Tutka P., Czuczwar S.J. Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Biochem Behav 2011, 98:261-267.
34. Luszczki J.J., Wojcik-Cwikla J., Andres M.M., Czuczwar S.J. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 2005, 30:958-973.
35. Luszczki J.J., Wojda E., Andres-Mach M.M., Cisowski W., Glensk M., Glowniak K., et al. Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res 2009, 85:293-299.
36. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992, 89:3825-3829.
37. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995, 15:6552-6561.
38. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
39. Mechoulam R., Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 2002, 121:35-43.
40. Meyer O.A., Tilson H.A., Byrd W.C., Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979, 1:233-236.
41. Naderi N., Aziz Ahari F., Shafaghi B., Najarkolaei A.H., Motamedi F. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J Neural Transm 2008, 115:1501-1511.
42. Sander J.W. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993, 34:1007-1016.
43. Sander J.W. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003, 16:165-170.
44. Shafaroodi H., Samini M., Moezi L., Homayoun H., Sadeghipour H., Tavacoli S., et al. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 2004, 47:390-400.
45. Shen M., Thayer S.A. The cannabinoid agonist WIN 55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res 1998, 783:77-84.
46. Shen M., Thayer S.A. Delta-9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 1999, 55:8-13.
47. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388:773-778.
48. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997, 78:43-50.
49. van Rijn C.M., Gaetani S., Santolini I., Badura A., Gabova A., Fu J., et al. WAG/Rij rats show a reduced expression of CB1 receptors in thalamic nuclei and respond to the CB1 receptor agonist, R(+)WIN55,212-2, with a reduced incidence of spike-wave discharges. Epilepsia 2010, 51:1511-1521.
50. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., et al. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 1986, 321:864-866.
51. Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., DeLorenzo R.J. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal epilepsy. J Pharmacol Exp Ther 2003, 307:129-137.
52. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoid in the modulation of seizure threshold and severity. Eur J Pharmacol 2002, 452:295-301.
53. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 2001, 428:51-57.